The pharmaceutical intermediate industry that you do not know about
Release time:
2018-11-05
【Abstract】Pharmaceutical intermediates refer to the chemical raw materials or chemical products needed in the synthesis process of drugs. These chemical products can be produced in ordinary chemical factories without obtaining a drug production license, as long as the Technical Index meets certain level requirements, they can be used to participate in the synthesis and production of drugs.
Pharmaceutical intermediates are chemical raw materials or chemical products needed in the synthesis process of drugs. These chemical products can be produced in ordinary chemical factories without obtaining a drug production license, as long as the technical index meets certain level requirements, they can be used to participate in the synthesis and production of drugs.
Although the synthesis of drugs also falls under the category of chemicals, the requirements are stricter than those for general chemical products. Manufacturers of finished drugs and raw materials need to undergo GMP certification, while manufacturers of intermediates do not, which lowers the industry entry threshold for intermediate manufacturers.
Overview of the development of the pharmaceutical intermediate industry in China
Data from IMS Health Incorporated shows that from 2010 to 2013, the global pharmaceutical market maintained a steady growth trend, increasing from $793.6 billion in 2010 to $899.3 billion in 2013. Starting in 2014, the pharmaceutical market showed rapid growth, mainly due to the large number of innovative drugs launched in the U.S. market in 2014, which reduced the impact of the patent cliff. The compound annual growth rate from 2010 to 2015 reached 6.14%. It is expected that from 2015 to 2019, the international pharmaceutical market will enter a slow growth cycle. However, due to the rigid demand for drugs, the net growth in the future is expected to be very strong, and by 2019, the global pharmaceutical market will approach $1.22 trillion.
Currently, with the restructuring of large multinational pharmaceutical companies, the transfer of multinational production, and further refinement of international division of labor, China has become an important production base for intermediates in the global pharmaceutical industry. China's pharmaceutical intermediate industry has formed a relatively complete system from research and development to production and sales. From the perspective of the development of pharmaceutical intermediates worldwide, China's overall process technology level is still at a relatively low position, with few manufacturers producing high-end pharmaceutical intermediates and supporting intermediate products for patented new drugs, currently in the stage of product structure optimization and upgrading.
Since 2011, the output value of China's chemical pharmaceutical intermediate industry has been increasing year by year, currently exceeding 200 billion yuan. The output of China's chemical pharmaceutical intermediates has also been growing year by year. In 2013, the output of China's chemical pharmaceutical intermediates was 568,300 tons, with an export volume of 65,700 tons. By 2015, the output of China's chemical pharmaceutical intermediates was approximately 676,400 tons.
Supply exceeds demand, relying on exports.
The overall market for pharmaceutical intermediates in China is characterized by supply exceeding demand and is extremely reliant on exports. China's exports are mainly concentrated in bulk products such as vitamin C, penicillin, acetaminophen, citric acid and its salts and esters. These bulk commodities have large output and many manufacturers, leading to intense competition. Some products with lower technical content are even oversupplied, resulting in an overall imbalance in supply and demand. Currently, many large enterprises are striving to improve the technical content of their products to change this supply-demand situation and increase the added value of their products.
Key words:
More information
New dispersants for multi-component dosage forms
The agrochemical market is developing towards water-based formulations with high content of active ingredients and multiple active ingredient combinations, thereby improving the efficacy of treatments. Different combinations of active ingredients that have the same efficacy but are based on different mechanisms are key to pest control and increasing yield, and are also a sustainable strategy.
Imidacloprid has a relatively high indoor toxicity to peanut root-knot nematodes.
Researchers from the College of Forestry at Henan University of Science and Technology used the immersion method to determine the toxicity of imidacloprid against second-stage larvae of root-knot nematodes, Pratylenchus brachyurus, Belonolaimus longicaudatus, pine wood nematodes, and rotten stem nematodes under different concentrations and times, and examined its effect on the egg hatching inhibition rate of root-knot nematodes.
The future prospects of biological pesticides are very promising.
Due to the rapid development of agriculture in recent years, the research and application technology of pesticides have not kept pace, leading to an increasing harm to the natural environment. The development of new safe, efficient, and green pesticides is urgent, and biological pesticides have come into people's view. The future development of biological pesticides is already an inevitable trend.
Handan Zhaodu Fine Chemicals Co., Ltd.
Phone: +86-13930087516
E-mail:info@zdchem.com
Address: East side of Ziyang Road, New Chemical Industrial Park, Handan, Guantao County, Hebei Province
